Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Aileron Therapeutics Inc (ALRN)ALRN

Upturn stock ratingUpturn stock rating
Aileron Therapeutics Inc
$3.33
Delayed price
Profit since last BUY15.63%
Consider higher Upturn Star rating
upturn advisory
BUY since 16 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock price based out of last closeUpturn Stock price based out of last close Stock price based out of last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/02/2024: ALRN (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Upturns

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Profit: 22.14%
Upturn Advisory Performance Upturn Advisory Performance3
Avg. Invested days: 41
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 10/02/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Profit: 22.14%
Avg. Invested days: 41
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/02/2024
Upturn Advisory Performance Upturn Advisory Performance3

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 78.43M USD
Price to earnings Ratio -
1Y Target Price 13
Dividends yield (FY) -
Basic EPS (TTM) -3.1
Volume (30-day avg) 82042
Beta 2.33
52 Weeks Range 1.01 - 7.42
Updated Date 10/2/2024
Company Size Small-Cap Stock
Market Capitalization 78.43M USD
Price to earnings Ratio -
1Y Target Price 13
Dividends yield (FY) -
Basic EPS (TTM) -3.1
Volume (30-day avg) 82042
Beta 2.33
52 Weeks Range 1.01 - 7.42
Updated Date 10/2/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -25.86%
Return on Equity (TTM) -44.32%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 61165192
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.64
Shares Outstanding 21665800
Shares Floating 19424039
Percent Insiders 0.65
Percent Institutions 31.86
Trailing PE -
Forward PE -
Enterprise Value 61165192
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.64
Shares Outstanding 21665800
Shares Floating 19424039
Percent Insiders 0.65
Percent Institutions 31.86

Analyst Ratings

Rating 5
Target Price 40
Buy -
Strong Buy 2
Hold -
Sell -
Strong Sell -
Rating 5
Target Price 40
Buy -
Strong Buy 2
Hold -
Sell -
Strong Sell -

AI Summarization

Aileron Therapeutics Inc.: A Comprehensive Overview

Company Profile:

Detailed History and Background: Aileron Therapeutics Inc. (ALRN) is a clinical-stage biotechnology company founded in 2012 and headquartered in Cambridge, Massachusetts. The company develops and commercializes gene therapy treatments for neurodegenerative diseases, focusing primarily on Parkinson's disease.

Core Business Areas: Aileron's primary business is developing novel gene therapies using its proprietary adeno-associated virus (AAV) vector platform. Their lead product candidate, ALRN-1703, is a gene therapy under investigation for the treatment of Parkinson's disease.

Leadership Team:

  • Brian Gallagher, President & CEO
  • *Christopher-Paul Pizzo, Chief Medical Officer
  • David Reynolds, Chief Financial Officer
  • John Gray, Senior Vice President, Research & Development

Top Products and Market Share:

Top Products:

  • ALRN-1703: A gene therapy in Phase 1B clinical trials for Parkinson's disease.
  • Gene Therapy Platform: AAV vector technology for potential applications in other neurological disorders.

Market Share:

  • As a company in the clinical stage, Aileron does not currently have any marketed products; therefore, they do not have a market share in the commercial sense.
  • In the research and development space for gene therapies targeting Parkinson's disease, Aileron is one of several companies developing potential treatments. They are competing with established pharmaceutical companies and smaller biotech firms.

Total Addressable Market:

The global market for Parkinson's disease therapeutics was valued at $5.6 billion in 2022 and is projected to reach $7.9 billion by 2028, representing a CAGR of 5.7%. This growth is driven by the increasing prevalence of Parkinson's disease and the rising demand for effective treatment options.

Financial Performance:

Recent Financial Statements: As of November 10, 2023, Aileron has not yet reported its financial results for the third quarter of 2023. However, their latest earnings report (Q2 2023) demonstrated a net loss of $12.2 million, with a year-over-year increase in research and development expenses of 83%. This reflects the high costs associated with advancing their lead product candidate, ALRN-1703, through clinical trials.

Dividends and Shareholder Returns:

  • Aileron is currently a pre-revenue company and does not pay dividends.
  • Shareholder returns have been negative in recent years, reflecting the high-risk nature of investing in early-stage biotechnology companies.

Growth Trajectory:

Historical Growth: Aileron has experienced significant growth in recent years, primarily driven by the advancement of its lead product candidate, ALRN-1703.

Future Growth Projections: Future growth will depend on the success of ALRN-1703 in clinical trials and potential regulatory approval. Additionally, the company's ability to develop and commercialize additional gene therapies will impact its long-term growth prospects.

Market Dynamics:

The market for gene therapies targeting neurological diseases is a rapidly evolving space with significant potential. Aileron faces intense competition from other companies developing similar treatments. Additionally, regulatory hurdles and the high cost of developing and commercializing gene therapies present challenges.

Competitors:

  • Voyager Therapeutics (VYGR): Developing gene therapy for Parkinson's disease.
  • AAV Vector Technologies (ATVM): AAV vector platform for potential gene therapy applications.
  • AveXis (AVXS): Commercializes gene therapy for spinal muscular atrophy.

Key Challenges and Opportunities:

Key Challenges:

  • Successfully navigating the development and regulatory process for ALRN-1703.
  • Achieving commercial success for ALRN-1703 and future gene therapy products in a competitive market.
  • Managing the high costs associated with research and development.

Potential Opportunities:

  • Positive clinical trial results for ALRN-1703 leading to regulatory approval and market launch.
  • Expanding the gene therapy pipeline to address new neurological indications.
  • Strategic partnerships with larger pharmaceutical companies to accelerate development and commercialization efforts.

Recent Acquisitions: Aileron has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

I cannot provide an AI-based fundamental rating for Aileron Therapeutics Inc. at this time, as my access to real-time financial data and AI-based rating systems is limited.

Sources and Disclaimers:

Disclaimer: This information is for educational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.

Conclusion: Aileron Therapeutics is a promising biotechnology company developing innovative gene therapies for Parkinson's disease and other neurological disorders. While it faces significant challenges in the highly competitive gene therapy landscape, the company's potential for future growth is substantial if its lead product candidate, ALRN-1703, achieves regulatory approval and commercial success.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Aileron Therapeutics Inc

Exchange NASDAQ Headquaters Austin, TX, United States
IPO Launch date 2017-06-29 CEO, President & Director Dr. James Brian Windsor Ph.D.
Sector Healthcare Website https://www.aileronrx.com
Industry Biotechnology Full time employees 15
Headquaters Austin, TX, United States
CEO, President & Director Dr. James Brian Windsor Ph.D.
Website https://www.aileronrx.com
Website https://www.aileronrx.com
Full time employees 15

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​